A new drug trend is creating concern across treatment centers, emergency departments, poison control networks, and clinical toxicology teams.

It is called 7-hydroxymitragynine, better known as 7-OH, 7-hydroxy, or 7-OHMG.

At first, many people hear “7-OH” and think it is just another kratom product. That is where the confusion begins.

The issue is not traditional kratom leaf. The issue is the rise of concentrated 7-OH products being sold as tablets, gummies, liquid shots, powders, drink mixes, extracts, and candy-like products. These products may be marketed as natural, plant-based, or kratom-related, but the clinical concern is very different.

Concentrated 7-OH can act like a potent opioid-like substance.

For treatment centers, the important question is no longer simply:

“Does this patient use kratom?”

The better question is:

“Is this patient using concentrated 7-OH without realizing the risk?”

“We are detecting 7-OH within recovery patient populations across the U.S. Only a handful of states currently have regulations in place to stop the sale of 7-OH. As we’ve seen with other emerging substances, valuable time is often lost before legislation can stop the distribution of new formulations.”

– Jibreel Sarij, CEO, Acutis Diagnostics.

Why This Matters Now

7-OH is gaining attention because it sits at the intersection of three problems:

• First, it is being sold through everyday retail channels such as smoke shops, vape shops, convenience stores, gas stations, and online stores.
• Second, many products are packaged in familiar forms: gummies, tablets, shots, powders, and flavored products. That makes them look closer to supplements or candy than to opioid-like substances.
• Third, many consumers may not understand what they are taking. A person may say they are using “kratom,” “hydroxy,” “7 tablets,” “gas station kratom,” or “natural pain relief,” while actually taking a concentrated 7-OH product.

That matters clinically because 7-OH has opioid-receptor activity and may be associated with dependence, withdrawal, respiratory depression, overdose-like toxicity, and severe adverse reactions.

The Key Difference: Kratom Leaf vs Concentrated 7-OH

This distinction is the center of the entire issue.

Traditional kratom leaf contains 7-OH only in low concentrations. Concentrated 7-OH products are different. These products may contain enhanced, semi-synthetic, or synthetic 7-OH at levels far beyond what would normally be expected in the plant.

That shift changes the risk profile.

A patient using traditional kratom powder and a patient using high-potency 7-OH gummies may both say “I use kratom,” but they may not be describing the same exposure.

This is where many articles and public conversations fall short. The debate often becomes “kratom is dangerous” versus “kratom is safe.” That framing is too broad.

The more useful clinical framing is:

Some products marketed as kratom may actually expose users to concentrated 7-OH, a much stronger opioid-like compound.

That is the point treatment centers, clinicians, and toxicology teams need to understand.

What 7-OH Can Look Like Clinically

Reported symptoms after 7-OH use include:

• Nausea and vomiting
• Agitation or confusion
• Sweating
• Rapid heart rate
• High blood pressure
• Trouble breathing
• Sleepiness or loss of consciousness
• Seizures
• Respiratory depression

The most serious concern is respiratory depression, especially when 7-OH is combined with alcohol, benzodiazepines, opioids, sedatives, antidepressants, or other substances.

Polysubstance use is one of the biggest risk multipliers. A patient may not be using 7-OH alone. They may be combining it with alcohol, cannabis, prescription medications, stimulants, or other drugs. That can make the clinical presentation more complex and more dangerous.

Because 7-OH acts on opioid receptors, naloxone may help reverse respiratory depression. However, patients may still need emergency monitoring, repeat dosing, and supportive care depending on the exposure and co-ingestants.

“7-OH is a strong reminder that today’s drug threats are not always entirely new substances; sometimes they are familiar compounds concentrated into far more potent and unpredictable forms. For clinicians and treatment providers, the challenge is recognizing these exposures early, especially when patients may describe them simply as ‘kratom’ or a smoke-shop product. This is where advanced toxicology becomes critical: it helps connect the clinical picture with what patients are actually using.” –  Dr Gregory Hobbs, Laboratory Director, Acutis Diagnostics.

Dependence and Withdrawal Are Part of the Concern

7-OH is not only an intoxication risk. It may also create dependence.

People using concentrated 7-OH products may report tolerance, cravings, dose escalation, and withdrawal. Withdrawal symptoms can include anxiety, restlessness, chills, diarrhea, abdominal cramping, nausea, vomiting, muscle aches, insomnia, sweating, fast heart rate, high blood pressure, and cravings.

This is especially important for treatment centers.

Some patients may come in saying they are using a legal supplement, not an opioid. Others may be using 7-OH to self-manage pain, anxiety, mood symptoms, or opioid withdrawal. But over time, they may develop a new pattern of dependence.

That means intake teams should ask about 7-OH directly.

Suggested intake language:

“Have you used any kratom products, 7-OH, 7-hydroxy, kratom shots, gummies, extracts, smoke-shop tablets, or products bought online for pain, mood, energy, sleep, or withdrawal?”

That one question can uncover exposure that standard drug-use screening may miss.

Why 7-OH May Be Underrecognized

7-OH may be more common than current numbers show.

There are several reasons for this:

• Patients may not know the product contains 7-OH.
• Packaging may be unclear or misleading.
• Products may be described only as kratom.
• Routine drug screens may not detect 7-OH.
• Surveillance systems may group cases under kratom rather than identifying concentrated 7-OH separately.
• Clinicians may not ask about it unless they know the product names.

This creates a blind spot.

A patient may present with opioid-like symptoms, withdrawal, relapse, or overdose risk, but the cause may not be obvious unless the care team specifically asks about emerging substances.

Why Clinical Toxicology Testing Matters

The 7-OH trend shows how quickly the drug market can move beyond routine screening.

When a patient presents with unexplained sedation, respiratory depression, seizure-like symptoms, withdrawal, or relapse but denies conventional opioid use, clinicians should consider emerging substances, including 7-OH.

Clinical toxicology testing can help clarify what the patient was actually exposed to, especially when history is unclear or product labeling is unreliable.

For treatment centers, this matters during:

• Intake assessment
• Withdrawal management
• Relapse evaluation
• Overdose-risk review
• Medication-assisted treatment planning
• Patient counseling
• Discharge planning

Better toxicology insight can help providers move from guessing to identifying.

“7-OH shows that the evolution of drug use isn’t just about new substances. The drug market continues to find new ways to concentrate, modify, and enhance substances, often creating products that are far more potent and unpredictable than their original forms. The onus is on laboratories to keep a pulse on what’s appearing on the street, so clinicians, treatment providers, and patients are not left relying on outdated testing that misses the substances actually being used.” – Jibreel Sarij, CEO, Acutis Diagnostics.

What Treatment Centers Should Do Now

Treatment centers do not need to wait for 7-OH to become a larger crisis before adapting.

They can start with four practical steps:

1. Update intake questions.
Ask specifically about 7-OH, 7-hydroxy, kratom shots, gummies, tablets, extracts, and smoke-shop or gas-station products.

2. Train clinical staff.
Make sure staff understand that “kratom use” may sometimes mean concentrated 7-OH exposure.

3. Watch for opioid-like signs.
Unexplained sedation, respiratory depression, withdrawal symptoms, seizures, or relapse should prompt more detailed questioning.

4. Use toxicology strategically.
When patient history and symptoms do not match routine screening, advanced clinical toxicology can help identify emerging substances.

The Bottom Line

7-OH is not just another supplement trend.

It is an emerging opioid-like exposure that may be hiding behind the language of kratom, wellness, pain relief, mood support, or natural alternatives.

The concern is not simply that 7-OH exists in the kratom plant. The concern is that concentrated 7-OH products are being sold in ways that may make consumers underestimate the risk.

For treatment centers and clinicians, the path forward is clear:

• Ask better questions.
• Recognize opioid-like toxicity.
• Consider targeted toxicology testing.
• Prepare for withdrawal and overdose risk.
• Educate patients before harm escalates.

7-OH is still an evolving issue, but the warning signs are already visible.